CORONA REMEDIES
Back to Balance Sheet
|
CORONA REMEDIES Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Total Non-Current Liabilities | ₹97 Cr | ₹84 Cr | ₹126 Cr | ₹45 Cr |
What is the latest Total Non-Current Liabilities ratio of CORONA REMEDIES ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹97 Cr |
| Mar2025 | ₹84 Cr |
| Mar2024 | ₹126 Cr |
| Mar2023 | ₹45 Cr |
How is Total Non-Current Liabilities of CORONA REMEDIES Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹97 Cr | 15.70 | |
| Mar2025 | ₹84 Cr | -33.38 | |
| Mar2024 | ₹126 Cr | 180.69 | |
| Mar2023 | ₹45 Cr | - | |
Compare Total Non-Current Liabilities of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹13,918.7 Cr | 3.5% | 12% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹425,150.0 Cr | 0.8% | -2.1% | 4.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹266,265.0 Cr | 4.9% | 7.9% | 54.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹176,300.0 Cr | 1.6% | -2.7% | 28.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,351.0 Cr | 2.6% | 14.2% | 3.9% | Stock Analytics | |
| CIPLA | ₹112,474.0 Cr | 2.4% | 3.4% | -12% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | 3.5% |
12% |
|
| SENSEX | 4.5% |
6.1% |
-9.3% |
You may also like the below Video Courses